Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Peritoneal Neoplasms | 92 | 2019 | 241 | 20.020 |
Why?
|
Hyperthermia, Induced | 83 | 2019 | 235 | 15.850 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 53 | 2019 | 146 | 11.060 |
Why?
|
Appendiceal Neoplasms | 27 | 2019 | 81 | 7.630 |
Why?
|
Adenocarcinoma | 48 | 2019 | 301 | 7.240 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 46 | 2019 | 401 | 7.240 |
Why?
|
Stomach Neoplasms | 29 | 2019 | 85 | 5.020 |
Why?
|
Breast Neoplasms | 42 | 2021 | 666 | 4.910 |
Why?
|
Combined Modality Therapy | 80 | 2019 | 525 | 4.730 |
Why?
|
Sentinel Lymph Node Biopsy | 23 | 2019 | 69 | 4.290 |
Why?
|
Antineoplastic Agents | 28 | 2018 | 546 | 4.100 |
Why?
|
Colorectal Neoplasms | 20 | 2018 | 208 | 3.830 |
Why?
|
Survival Rate | 77 | 2019 | 795 | 3.780 |
Why?
|
Neoplasm Staging | 68 | 2021 | 436 | 3.690 |
Why?
|
Neoplasm Recurrence, Local | 31 | 2019 | 337 | 3.590 |
Why?
|
Middle Aged | 180 | 2021 | 10829 | 3.530 |
Why?
|
Carcinoma | 16 | 2016 | 87 | 3.380 |
Why?
|
Humans | 248 | 2021 | 29093 | 3.130 |
Why?
|
Female | 198 | 2021 | 18164 | 3.060 |
Why?
|
Adult | 131 | 2021 | 8420 | 2.990 |
Why?
|
Melanoma | 12 | 2019 | 148 | 2.920 |
Why?
|
Aged | 135 | 2021 | 9487 | 2.850 |
Why?
|
Postoperative Complications | 26 | 2018 | 670 | 2.720 |
Why?
|
Mitomycin | 19 | 2018 | 45 | 2.660 |
Why?
|
Prognosis | 67 | 2019 | 1362 | 2.650 |
Why?
|
Retrospective Studies | 91 | 2019 | 3111 | 2.640 |
Why?
|
Male | 154 | 2019 | 17807 | 2.540 |
Why?
|
Follow-Up Studies | 64 | 2021 | 2108 | 2.400 |
Why?
|
Treatment Outcome | 68 | 2021 | 3099 | 2.380 |
Why?
|
Skin Neoplasms | 10 | 2019 | 206 | 2.370 |
Why?
|
Adrenal Cortex Neoplasms | 16 | 2019 | 34 | 2.310 |
Why?
|
Adrenocortical Carcinoma | 16 | 2019 | 34 | 2.310 |
Why?
|
Lymph Nodes | 13 | 2018 | 92 | 2.220 |
Why?
|
Aged, 80 and over | 69 | 2021 | 3717 | 2.180 |
Why?
|
Colonic Neoplasms | 9 | 2016 | 63 | 2.150 |
Why?
|
Chemotherapy, Adjuvant | 31 | 2019 | 163 | 2.140 |
Why?
|
Mesothelioma | 10 | 2019 | 38 | 2.040 |
Why?
|
Gastrectomy | 22 | 2018 | 65 | 2.020 |
Why?
|
Quality of Life | 13 | 2019 | 816 | 1.950 |
Why?
|
Liver Neoplasms | 13 | 2018 | 162 | 1.940 |
Why?
|
Prospective Studies | 41 | 2021 | 2019 | 1.830 |
Why?
|
Esophageal Neoplasms | 6 | 2014 | 33 | 1.780 |
Why?
|
Infusions, Parenteral | 22 | 2016 | 64 | 1.750 |
Why?
|
Mastectomy | 13 | 2019 | 59 | 1.620 |
Why?
|
Lymphatic Metastasis | 28 | 2018 | 156 | 1.610 |
Why?
|
Lymph Node Excision | 18 | 2019 | 89 | 1.610 |
Why?
|
Radiography, Thoracic | 2 | 2019 | 43 | 1.350 |
Why?
|
Radiopharmaceuticals | 9 | 2010 | 87 | 1.350 |
Why?
|
Pseudomyxoma Peritonei | 7 | 2014 | 12 | 1.340 |
Why?
|
Neoplasms | 12 | 2019 | 610 | 1.340 |
Why?
|
Young Adult | 29 | 2019 | 2402 | 1.130 |
Why?
|
Mammaplasty | 6 | 2013 | 27 | 1.130 |
Why?
|
Antibiotics, Antineoplastic | 8 | 2011 | 62 | 1.110 |
Why?
|
Fluorodeoxyglucose F18 | 7 | 2010 | 56 | 1.090 |
Why?
|
Survival Analysis | 30 | 2017 | 440 | 1.080 |
Why?
|
Organoplatinum Compounds | 5 | 2013 | 42 | 1.000 |
Why?
|
Rectal Neoplasms | 4 | 2013 | 14 | 0.990 |
Why?
|
Jejunal Neoplasms | 3 | 2013 | 7 | 0.990 |
Why?
|
Adrenalectomy | 8 | 2018 | 29 | 0.950 |
Why?
|
Disease-Free Survival | 22 | 2018 | 281 | 0.900 |
Why?
|
Positron-Emission Tomography | 6 | 2010 | 172 | 0.890 |
Why?
|
Predictive Value of Tests | 14 | 2019 | 787 | 0.890 |
Why?
|
Mastectomy, Segmental | 7 | 2021 | 23 | 0.870 |
Why?
|
Duodenal Neoplasms | 2 | 2013 | 6 | 0.860 |
Why?
|
Peritoneum | 6 | 2013 | 24 | 0.850 |
Why?
|
Blood Cell Count | 2 | 2019 | 26 | 0.840 |
Why?
|
Morbidity | 10 | 2017 | 91 | 0.830 |
Why?
|
Mutation | 6 | 2017 | 466 | 0.810 |
Why?
|
Carcinoma, Lobular | 4 | 2015 | 12 | 0.800 |
Why?
|
Adenocarcinoma, Mucinous | 3 | 2014 | 20 | 0.790 |
Why?
|
Neoplasm Invasiveness | 12 | 2017 | 189 | 0.760 |
Why?
|
Surgical Wound Infection | 3 | 2019 | 74 | 0.750 |
Why?
|
Abdominal Neoplasms | 3 | 2014 | 15 | 0.750 |
Why?
|
Ileal Neoplasms | 2 | 2013 | 4 | 0.740 |
Why?
|
Hepatectomy | 8 | 2018 | 66 | 0.740 |
Why?
|
Ovarian Neoplasms | 5 | 2016 | 87 | 0.740 |
Why?
|
Negative-Pressure Wound Therapy | 2 | 2019 | 43 | 0.730 |
Why?
|
Pancreatectomy | 5 | 2019 | 29 | 0.720 |
Why?
|
Gynecology | 1 | 2019 | 15 | 0.710 |
Why?
|
Obstetrics | 1 | 2019 | 16 | 0.710 |
Why?
|
Workplace | 1 | 2019 | 47 | 0.690 |
Why?
|
Liver Function Tests | 1 | 2019 | 19 | 0.690 |
Why?
|
Burnout, Professional | 1 | 2019 | 44 | 0.670 |
Why?
|
Esophagectomy | 4 | 2014 | 15 | 0.670 |
Why?
|
Severity of Illness Index | 4 | 2018 | 863 | 0.670 |
Why?
|
Carcinoma, Merkel Cell | 2 | 2009 | 10 | 0.670 |
Why?
|
Adolescent | 21 | 2018 | 3254 | 0.670 |
Why?
|
Pancreatic Neoplasms | 6 | 2019 | 131 | 0.670 |
Why?
|
Sarcoma | 4 | 2019 | 56 | 0.660 |
Why?
|
Rosaniline Dyes | 6 | 2009 | 19 | 0.650 |
Why?
|
United States | 32 | 2019 | 3630 | 0.650 |
Why?
|
Enteral Nutrition | 2 | 2015 | 30 | 0.630 |
Why?
|
Neoplasms, Glandular and Epithelial | 3 | 2016 | 10 | 0.620 |
Why?
|
Digestive System Neoplasms | 1 | 2017 | 4 | 0.600 |
Why?
|
Laparotomy | 1 | 2017 | 32 | 0.590 |
Why?
|
Neoadjuvant Therapy | 4 | 2013 | 56 | 0.580 |
Why?
|
Cohort Studies | 14 | 2018 | 1687 | 0.580 |
Why?
|
Coloring Agents | 4 | 2009 | 30 | 0.580 |
Why?
|
Sensitivity and Specificity | 13 | 2018 | 532 | 0.580 |
Why?
|
Carboplatin | 4 | 2013 | 40 | 0.560 |
Why?
|
Gene Expression Profiling | 3 | 2017 | 320 | 0.540 |
Why?
|
Proportional Hazards Models | 13 | 2017 | 709 | 0.530 |
Why?
|
Leiomyosarcoma | 3 | 2010 | 8 | 0.510 |
Why?
|
Length of Stay | 7 | 2017 | 292 | 0.510 |
Why?
|
Intraoperative Care | 7 | 2015 | 48 | 0.500 |
Why?
|
Genetic Testing | 2 | 2013 | 90 | 0.500 |
Why?
|
Angiogenesis Inhibitors | 1 | 2014 | 34 | 0.500 |
Why?
|
Thalidomide | 1 | 2014 | 29 | 0.500 |
Why?
|
Registries | 9 | 2018 | 278 | 0.490 |
Why?
|
Cytological Techniques | 2 | 2011 | 19 | 0.480 |
Why?
|
Multivariate Analysis | 10 | 2016 | 637 | 0.480 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2017 | 179 | 0.470 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 4 | 2009 | 17 | 0.460 |
Why?
|
Adjuvants, Immunologic | 2 | 2011 | 51 | 0.460 |
Why?
|
Nipples | 1 | 2013 | 3 | 0.460 |
Why?
|
Breast Diseases | 1 | 2013 | 4 | 0.460 |
Why?
|
Databases, Factual | 11 | 2018 | 332 | 0.450 |
Why?
|
Carcinoma, Ductal, Breast | 4 | 2011 | 28 | 0.450 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2009 | 249 | 0.440 |
Why?
|
Pancreaticoduodenectomy | 2 | 2019 | 21 | 0.440 |
Why?
|
Retroperitoneal Neoplasms | 2 | 2019 | 11 | 0.430 |
Why?
|
Intraoperative Period | 6 | 2011 | 37 | 0.430 |
Why?
|
BCG Vaccine | 1 | 2011 | 7 | 0.420 |
Why?
|
Mastectomy, Modified Radical | 1 | 2011 | 2 | 0.410 |
Why?
|
Genes, BRCA2 | 2 | 2011 | 7 | 0.410 |
Why?
|
Biopsy, Needle | 4 | 2005 | 89 | 0.410 |
Why?
|
Cisplatin | 6 | 2014 | 69 | 0.410 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2011 | 5 | 0.400 |
Why?
|
Secondary Prevention | 1 | 2011 | 59 | 0.400 |
Why?
|
Lung Neoplasms | 5 | 2017 | 384 | 0.400 |
Why?
|
Societies, Medical | 2 | 2016 | 149 | 0.390 |
Why?
|
Adenoma | 1 | 2011 | 35 | 0.390 |
Why?
|
Medical Oncology | 1 | 2011 | 70 | 0.390 |
Why?
|
Histocytological Preparation Techniques | 1 | 2010 | 2 | 0.380 |
Why?
|
Thoracoscopy | 1 | 2010 | 9 | 0.380 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 2 | 2009 | 6 | 0.370 |
Why?
|
Colectomy | 3 | 2014 | 25 | 0.360 |
Why?
|
Nutrition Assessment | 2 | 2014 | 54 | 0.360 |
Why?
|
Mammography | 4 | 2005 | 37 | 0.360 |
Why?
|
Tomography, Emission-Computed | 3 | 2005 | 25 | 0.350 |
Why?
|
Subcutaneous Tissue | 1 | 2009 | 6 | 0.350 |
Why?
|
Neoplasms, Connective Tissue | 1 | 2009 | 2 | 0.350 |
Why?
|
Risk Factors | 14 | 2018 | 3531 | 0.350 |
Why?
|
Diagnostic Tests, Routine | 2 | 2019 | 23 | 0.350 |
Why?
|
Incidence | 8 | 2018 | 1119 | 0.340 |
Why?
|
Uterine Neoplasms | 1 | 2009 | 23 | 0.340 |
Why?
|
Disease Progression | 7 | 2017 | 572 | 0.340 |
Why?
|
Neuroendocrine Tumors | 2 | 2019 | 20 | 0.330 |
Why?
|
Yoga | 1 | 2009 | 41 | 0.330 |
Why?
|
Pregnancy Complications, Neoplastic | 2 | 2011 | 4 | 0.320 |
Why?
|
Pleural Neoplasms | 2 | 2007 | 11 | 0.320 |
Why?
|
Catheter Ablation | 3 | 2004 | 62 | 0.320 |
Why?
|
Radiotherapy, Adjuvant | 12 | 2012 | 68 | 0.320 |
Why?
|
Anesthesia, Conduction | 2 | 2018 | 29 | 0.310 |
Why?
|
Fertility Agents, Female | 1 | 2007 | 8 | 0.310 |
Why?
|
Leuprolide | 1 | 2007 | 8 | 0.310 |
Why?
|
Frozen Sections | 4 | 2014 | 18 | 0.310 |
Why?
|
Breast Neoplasms, Male | 1 | 2007 | 11 | 0.310 |
Why?
|
Microwaves | 1 | 2007 | 8 | 0.310 |
Why?
|
Biopsy, Fine-Needle | 3 | 2007 | 50 | 0.310 |
Why?
|
Electrocoagulation | 1 | 2007 | 12 | 0.300 |
Why?
|
Deoxycytidine | 5 | 2013 | 63 | 0.300 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2012 | 142 | 0.300 |
Why?
|
Mental Health | 2 | 2019 | 104 | 0.300 |
Why?
|
Polymorphism, Genetic | 4 | 2011 | 196 | 0.300 |
Why?
|
Logistic Models | 7 | 2018 | 727 | 0.290 |
Why?
|
Focal Nodular Hyperplasia | 1 | 2006 | 3 | 0.290 |
Why?
|
Health Status | 4 | 2016 | 368 | 0.290 |
Why?
|
Hemoperitoneum | 1 | 2006 | 4 | 0.290 |
Why?
|
Patient Readmission | 3 | 2016 | 105 | 0.290 |
Why?
|
Activities of Daily Living | 4 | 2011 | 238 | 0.280 |
Why?
|
Child | 7 | 2014 | 2219 | 0.280 |
Why?
|
Blood Transfusion | 2 | 2017 | 64 | 0.280 |
Why?
|
Obesity | 1 | 2013 | 1063 | 0.280 |
Why?
|
Head and Neck Neoplasms | 1 | 2007 | 117 | 0.270 |
Why?
|
DNA Repair | 4 | 2014 | 50 | 0.270 |
Why?
|
Nomograms | 2 | 2016 | 30 | 0.270 |
Why?
|
European Continental Ancestry Group | 4 | 2017 | 1131 | 0.270 |
Why?
|
Neoplasm Metastasis | 8 | 2019 | 199 | 0.260 |
Why?
|
Jejunostomy | 2 | 2015 | 5 | 0.260 |
Why?
|
Receptor, erbB-2 | 2 | 2014 | 45 | 0.260 |
Why?
|
North Carolina | 8 | 2015 | 1423 | 0.260 |
Why?
|
Preoperative Care | 3 | 2013 | 110 | 0.260 |
Why?
|
Gallbladder Neoplasms | 2 | 2015 | 33 | 0.260 |
Why?
|
Pilot Projects | 6 | 2014 | 469 | 0.260 |
Why?
|
Liposarcoma, Myxoid | 1 | 2004 | 1 | 0.260 |
Why?
|
Intussusception | 1 | 2004 | 2 | 0.260 |
Why?
|
Reoperation | 5 | 2017 | 203 | 0.250 |
Why?
|
Genetic Markers | 2 | 2015 | 122 | 0.240 |
Why?
|
Genes, erbB-2 | 1 | 2003 | 5 | 0.240 |
Why?
|
Cluster Analysis | 2 | 2015 | 128 | 0.240 |
Why?
|
Blood Platelets | 2 | 2015 | 37 | 0.240 |
Why?
|
Prostatic Neoplasms | 2 | 2013 | 441 | 0.240 |
Why?
|
Parathyroid Neoplasms | 1 | 2003 | 7 | 0.240 |
Why?
|
Feasibility Studies | 5 | 2018 | 263 | 0.240 |
Why?
|
Ethnic Groups | 3 | 2016 | 440 | 0.240 |
Why?
|
Age Factors | 8 | 2017 | 1108 | 0.240 |
Why?
|
Vascular Surgical Procedures | 3 | 2015 | 91 | 0.230 |
Why?
|
Reproducibility of Results | 5 | 2015 | 726 | 0.230 |
Why?
|
Camptothecin | 2 | 2005 | 48 | 0.230 |
Why?
|
Neutrophils | 2 | 2015 | 102 | 0.230 |
Why?
|
Breast | 1 | 2003 | 53 | 0.230 |
Why?
|
Surgical Flaps | 3 | 2013 | 69 | 0.220 |
Why?
|
Pregnancy | 3 | 2019 | 815 | 0.220 |
Why?
|
Interferon-alpha | 1 | 2003 | 69 | 0.220 |
Why?
|
Genes, p53 | 3 | 2017 | 23 | 0.220 |
Why?
|
Cytodiagnosis | 3 | 2011 | 16 | 0.220 |
Why?
|
DNA, Neoplasm | 2 | 2017 | 58 | 0.220 |
Why?
|
Clinical Trials as Topic | 3 | 2009 | 298 | 0.210 |
Why?
|
Injections, Intraperitoneal | 5 | 2014 | 41 | 0.210 |
Why?
|
Lymphocytes | 2 | 2015 | 53 | 0.210 |
Why?
|
Biopsy | 2 | 2015 | 241 | 0.200 |
Why?
|
Hospital Mortality | 3 | 2017 | 186 | 0.200 |
Why?
|
Consensus | 2 | 2013 | 68 | 0.200 |
Why?
|
Anus Neoplasms | 2 | 2012 | 9 | 0.190 |
Why?
|
Pelvis | 2 | 2018 | 61 | 0.190 |
Why?
|
Necrosis | 2 | 2013 | 53 | 0.190 |
Why?
|
Radiotherapy Dosage | 4 | 2010 | 98 | 0.180 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2013 | 464 | 0.180 |
Why?
|
Patient Selection | 3 | 2017 | 257 | 0.180 |
Why?
|
Peritoneal Lavage | 1 | 2019 | 2 | 0.180 |
Why?
|
Splenectomy | 3 | 2017 | 19 | 0.180 |
Why?
|
Leadership | 1 | 2019 | 34 | 0.170 |
Why?
|
Tissue Array Analysis | 1 | 2019 | 34 | 0.170 |
Why?
|
Immunohistochemistry | 4 | 2008 | 519 | 0.170 |
Why?
|
Seroma | 1 | 2019 | 3 | 0.170 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2015 | 35 | 0.170 |
Why?
|
Laparoscopy | 2 | 2019 | 169 | 0.170 |
Why?
|
Odds Ratio | 7 | 2015 | 447 | 0.170 |
Why?
|
Myeloid Cells | 1 | 2019 | 35 | 0.170 |
Why?
|
Surgical Wound Dehiscence | 1 | 2019 | 11 | 0.170 |
Why?
|
Self Efficacy | 1 | 2019 | 70 | 0.170 |
Why?
|
Lower Gastrointestinal Tract | 1 | 2018 | 3 | 0.170 |
Why?
|
Depression | 3 | 2007 | 380 | 0.170 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2018 | 50 | 0.170 |
Why?
|
Time Factors | 6 | 2017 | 2001 | 0.170 |
Why?
|
Vascular Neoplasms | 2 | 2010 | 14 | 0.160 |
Why?
|
Cell Proliferation | 2 | 2018 | 573 | 0.160 |
Why?
|
Digestive System Surgical Procedures | 2 | 2011 | 20 | 0.160 |
Why?
|
Pain Measurement | 2 | 2018 | 364 | 0.160 |
Why?
|
Diagnosis, Differential | 5 | 2015 | 493 | 0.160 |
Why?
|
Intestinal Neoplasms | 1 | 2018 | 4 | 0.160 |
Why?
|
Vena Cava, Inferior | 2 | 2010 | 31 | 0.160 |
Why?
|
Urachus | 1 | 2017 | 3 | 0.160 |
Why?
|
Practice Guidelines as Topic | 2 | 2013 | 374 | 0.160 |
Why?
|
Appendectomy | 1 | 2018 | 15 | 0.160 |
Why?
|
Organoids | 1 | 2018 | 68 | 0.160 |
Why?
|
Intensive Care Units | 2 | 2015 | 118 | 0.160 |
Why?
|
Risk Assessment | 7 | 2017 | 1305 | 0.150 |
Why?
|
Disease Management | 1 | 2018 | 114 | 0.150 |
Why?
|
Hospital Charges | 1 | 2017 | 13 | 0.150 |
Why?
|
Diaphragm | 2 | 2014 | 46 | 0.150 |
Why?
|
Crohn Disease | 1 | 2017 | 25 | 0.150 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2017 | 23 | 0.150 |
Why?
|
Medicaid | 2 | 2008 | 83 | 0.150 |
Why?
|
Intestinal Perforation | 1 | 2016 | 9 | 0.150 |
Why?
|
Cross Infection | 1 | 2017 | 46 | 0.150 |
Why?
|
Decision Support Techniques | 1 | 2018 | 104 | 0.150 |
Why?
|
Lymphedema | 2 | 2017 | 4 | 0.140 |
Why?
|
Vomiting | 2 | 2014 | 24 | 0.140 |
Why?
|
Models, Biological | 1 | 2018 | 373 | 0.140 |
Why?
|
Emotions | 1 | 2016 | 48 | 0.140 |
Why?
|
Nausea | 2 | 2014 | 49 | 0.140 |
Why?
|
Taxoids | 2 | 2013 | 47 | 0.140 |
Why?
|
Mitotane | 1 | 2015 | 2 | 0.140 |
Why?
|
Gastric Stump | 1 | 2015 | 2 | 0.140 |
Why?
|
Linitis Plastica | 1 | 2015 | 2 | 0.140 |
Why?
|
Gastroenterostomy | 1 | 2015 | 2 | 0.140 |
Why?
|
Anastomosis, Roux-en-Y | 1 | 2015 | 3 | 0.140 |
Why?
|
African Americans | 3 | 2017 | 1373 | 0.140 |
Why?
|
Biliary Tract Surgical Procedures | 1 | 2015 | 7 | 0.140 |
Why?
|
Peritoneal Stomata | 1 | 2015 | 3 | 0.130 |
Why?
|
Bile Ducts | 1 | 2015 | 18 | 0.130 |
Why?
|
Tumor Cells, Cultured | 4 | 2018 | 158 | 0.130 |
Why?
|
Forecasting | 1 | 2016 | 133 | 0.130 |
Why?
|
Bile Duct Neoplasms | 1 | 2015 | 36 | 0.130 |
Why?
|
Patient Admission | 1 | 2015 | 53 | 0.130 |
Why?
|
Genetic Predisposition to Disease | 3 | 2014 | 836 | 0.130 |
Why?
|
Blood Vessels | 1 | 2015 | 47 | 0.130 |
Why?
|
Anemia | 1 | 2015 | 55 | 0.130 |
Why?
|
Animals | 4 | 2013 | 7297 | 0.130 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2014 | 6 | 0.130 |
Why?
|
Skilled Nursing Facilities | 1 | 2014 | 9 | 0.130 |
Why?
|
Anastomosis, Surgical | 2 | 2015 | 49 | 0.130 |
Why?
|
Drug Therapy, Combination | 2 | 2013 | 273 | 0.130 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2014 | 12 | 0.130 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2014 | 37 | 0.130 |
Why?
|
Abdominal Cavity | 1 | 2014 | 6 | 0.130 |
Why?
|
Gastrostomy | 1 | 2014 | 17 | 0.120 |
Why?
|
Thromboembolism | 1 | 2014 | 30 | 0.120 |
Why?
|
Appendix | 1 | 2014 | 4 | 0.120 |
Why?
|
Nervous System Diseases | 1 | 2014 | 37 | 0.120 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2014 | 32 | 0.120 |
Why?
|
Neoplasm, Residual | 3 | 2016 | 23 | 0.120 |
Why?
|
Thiosulfates | 1 | 2013 | 3 | 0.120 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2013 | 21 | 0.120 |
Why?
|
Ascites | 1 | 2013 | 13 | 0.120 |
Why?
|
Urinary Tract | 1 | 2013 | 21 | 0.120 |
Why?
|
Urologic Diseases | 1 | 2013 | 28 | 0.120 |
Why?
|
Reconstructive Surgical Procedures | 1 | 2015 | 190 | 0.120 |
Why?
|
Patient Discharge | 1 | 2014 | 168 | 0.120 |
Why?
|
Comparative Effectiveness Research | 1 | 2013 | 23 | 0.120 |
Why?
|
BRCA2 Protein | 1 | 2013 | 2 | 0.110 |
Why?
|
Tumor Burden | 3 | 2017 | 60 | 0.110 |
Why?
|
BRCA1 Protein | 1 | 2013 | 10 | 0.110 |
Why?
|
Genomics | 1 | 2013 | 82 | 0.110 |
Why?
|
Anthracyclines | 1 | 2013 | 51 | 0.110 |
Why?
|
Genotype | 2 | 2012 | 735 | 0.110 |
Why?
|
Fatty Acids | 1 | 2013 | 92 | 0.110 |
Why?
|
Maximum Tolerated Dose | 2 | 2012 | 56 | 0.110 |
Why?
|
Body Mass Index | 3 | 2016 | 865 | 0.110 |
Why?
|
Tissue Expansion Devices | 1 | 2011 | 10 | 0.110 |
Why?
|
Immunotherapy, Active | 1 | 2011 | 6 | 0.100 |
Why?
|
Diet | 1 | 2014 | 354 | 0.100 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2011 | 26 | 0.100 |
Why?
|
Clinical Competence | 1 | 2014 | 307 | 0.100 |
Why?
|
Genes, BRCA1 | 1 | 2011 | 9 | 0.100 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 207 | 0.100 |
Why?
|
Immunoenzyme Techniques | 3 | 2015 | 46 | 0.100 |
Why?
|
Chi-Square Distribution | 3 | 2009 | 293 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2014 | 1079 | 0.100 |
Why?
|
Magnetic Resonance Imaging | 2 | 2018 | 1218 | 0.100 |
Why?
|
Heterozygote | 1 | 2011 | 52 | 0.100 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2012 | 155 | 0.100 |
Why?
|
Diabetes Mellitus | 1 | 2014 | 366 | 0.100 |
Why?
|
Case-Control Studies | 5 | 2014 | 859 | 0.100 |
Why?
|
Sleep | 1 | 2012 | 86 | 0.100 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2011 | 8 | 0.100 |
Why?
|
Pancreatitis | 1 | 2011 | 18 | 0.100 |
Why?
|
Organizational Objectives | 1 | 2010 | 22 | 0.100 |
Why?
|
Poverty | 2 | 2008 | 99 | 0.100 |
Why?
|
Cooperative Behavior | 1 | 2010 | 73 | 0.090 |
Why?
|
Smoking | 2 | 2017 | 427 | 0.090 |
Why?
|
Phenotype | 1 | 2012 | 629 | 0.090 |
Why?
|
Patient Satisfaction | 1 | 2011 | 222 | 0.090 |
Why?
|
Research Design | 1 | 2012 | 286 | 0.090 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 159 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 3 | 2018 | 871 | 0.090 |
Why?
|
Fluorouracil | 4 | 2012 | 73 | 0.090 |
Why?
|
Medical Records | 4 | 2012 | 68 | 0.090 |
Why?
|
Equipment Design | 2 | 2007 | 167 | 0.090 |
Why?
|
Protein Biosynthesis | 1 | 2009 | 46 | 0.090 |
Why?
|
Hysterectomy | 1 | 2009 | 37 | 0.080 |
Why?
|
Colonoscopy | 1 | 2008 | 41 | 0.080 |
Why?
|
Multifactorial Inheritance | 1 | 2008 | 19 | 0.080 |
Why?
|
Glutathione S-Transferase pi | 1 | 2008 | 6 | 0.080 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 6 | 0.080 |
Why?
|
Glutathione Transferase | 1 | 2008 | 18 | 0.080 |
Why?
|
Telomere | 1 | 2008 | 10 | 0.080 |
Why?
|
Models, Genetic | 1 | 2008 | 92 | 0.080 |
Why?
|
Comorbidity | 3 | 2017 | 540 | 0.080 |
Why?
|
Radiation Tolerance | 1 | 2008 | 22 | 0.080 |
Why?
|
Cross-Sectional Studies | 1 | 2012 | 1356 | 0.080 |
Why?
|
Ascitic Fluid | 1 | 2007 | 7 | 0.080 |
Why?
|
Radiation Injuries | 1 | 2008 | 67 | 0.080 |
Why?
|
Leg | 1 | 2007 | 56 | 0.080 |
Why?
|
Paclitaxel | 3 | 2013 | 50 | 0.080 |
Why?
|
Neck | 1 | 2007 | 26 | 0.080 |
Why?
|
NAD | 1 | 2007 | 25 | 0.080 |
Why?
|
Hematologic Diseases | 1 | 2007 | 23 | 0.080 |
Why?
|
Neoplasm Proteins | 3 | 2017 | 141 | 0.080 |
Why?
|
Cell Death | 1 | 2007 | 71 | 0.080 |
Why?
|
Health Surveys | 1 | 2007 | 191 | 0.080 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 139 | 0.070 |
Why?
|
Neutropenia | 2 | 2008 | 23 | 0.070 |
Why?
|
Patient Participation | 1 | 2007 | 62 | 0.070 |
Why?
|
Health Promotion | 1 | 2009 | 220 | 0.070 |
Why?
|
Carcinoembryonic Antigen | 1 | 2006 | 7 | 0.070 |
Why?
|
Exercise | 1 | 2011 | 591 | 0.070 |
Why?
|
False Negative Reactions | 1 | 2006 | 21 | 0.070 |
Why?
|
Keratins | 1 | 2006 | 36 | 0.070 |
Why?
|
Rupture | 1 | 2006 | 29 | 0.070 |
Why?
|
Axilla | 2 | 2003 | 15 | 0.070 |
Why?
|
Fluorescent Dyes | 1 | 2006 | 45 | 0.070 |
Why?
|
Telomerase | 1 | 2006 | 21 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2012 | 641 | 0.070 |
Why?
|
Survival | 1 | 2006 | 13 | 0.070 |
Why?
|
Continental Population Groups | 1 | 2007 | 221 | 0.070 |
Why?
|
Endosonography | 1 | 2006 | 56 | 0.070 |
Why?
|
Suture Techniques | 1 | 2006 | 56 | 0.070 |
Why?
|
International Agencies | 2 | 2017 | 6 | 0.070 |
Why?
|
Hemangioma, Cavernous | 1 | 2004 | 3 | 0.060 |
Why?
|
Drug Administration Schedule | 3 | 2012 | 246 | 0.060 |
Why?
|
Nevus | 1 | 2004 | 15 | 0.060 |
Why?
|
Malignant Carcinoid Syndrome | 1 | 2003 | 1 | 0.060 |
Why?
|
Gene Amplification | 1 | 2003 | 9 | 0.060 |
Why?
|
Anoikis | 1 | 2003 | 2 | 0.060 |
Why?
|
Tropomyosin | 1 | 2003 | 3 | 0.060 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2003 | 37 | 0.060 |
Why?
|
Monitoring, Intraoperative | 1 | 2004 | 39 | 0.060 |
Why?
|
Hypercalcemia | 1 | 2003 | 8 | 0.060 |
Why?
|
Hyperplasia | 1 | 2003 | 38 | 0.060 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2003 | 13 | 0.060 |
Why?
|
Regression Analysis | 1 | 2004 | 274 | 0.060 |
Why?
|
Massage | 1 | 2003 | 11 | 0.060 |
Why?
|
Preoperative Period | 2 | 2014 | 31 | 0.060 |
Why?
|
Flow Cytometry | 1 | 2003 | 171 | 0.060 |
Why?
|
Drosophila Proteins | 1 | 2003 | 43 | 0.060 |
Why?
|
Cell Biology | 1 | 2002 | 2 | 0.060 |
Why?
|
Specimen Handling | 1 | 2002 | 31 | 0.060 |
Why?
|
Cryopreservation | 1 | 2002 | 42 | 0.050 |
Why?
|
Recombinant Proteins | 1 | 2003 | 248 | 0.050 |
Why?
|
Health Services Accessibility | 2 | 2019 | 231 | 0.050 |
Why?
|
Postoperative Care | 2 | 2018 | 72 | 0.050 |
Why?
|
Polymerase Chain Reaction | 3 | 2008 | 172 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2003 | 242 | 0.050 |
Why?
|
Tissue Fixation | 1 | 2019 | 10 | 0.040 |
Why?
|
Paraffin Embedding | 1 | 2019 | 10 | 0.040 |
Why?
|
Remission Induction | 2 | 2010 | 78 | 0.040 |
Why?
|
Formaldehyde | 1 | 2019 | 11 | 0.040 |
Why?
|
Pancreatic Diseases | 1 | 2019 | 16 | 0.040 |
Why?
|
Single-Blind Method | 2 | 2011 | 165 | 0.040 |
Why?
|
Reference Values | 1 | 2018 | 224 | 0.040 |
Why?
|
Intestine, Small | 1 | 2018 | 34 | 0.040 |
Why?
|
Cell Survival | 1 | 2018 | 272 | 0.040 |
Why?
|
ROC Curve | 1 | 2018 | 149 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2017 | 16 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2017 | 23 | 0.040 |
Why?
|
Genes, erbB-1 | 1 | 2017 | 15 | 0.040 |
Why?
|
Clone Cells | 1 | 2017 | 36 | 0.040 |
Why?
|
Genes, Neoplasm | 1 | 2017 | 18 | 0.040 |
Why?
|
Genes, ras | 1 | 2017 | 26 | 0.040 |
Why?
|
DNA-Binding Proteins | 2 | 2011 | 142 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 69 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 77 | 0.040 |
Why?
|
Recovery of Function | 1 | 2018 | 190 | 0.040 |
Why?
|
Diarrhea | 2 | 2008 | 56 | 0.040 |
Why?
|
Heart Diseases | 1 | 2017 | 97 | 0.040 |
Why?
|
Neoplastic Stem Cells | 1 | 2017 | 90 | 0.040 |
Why?
|
Pancreatic Fistula | 1 | 2016 | 3 | 0.040 |
Why?
|
Postoperative Period | 1 | 2016 | 91 | 0.030 |
Why?
|
Abdomen | 1 | 2016 | 42 | 0.030 |
Why?
|
Chemoprevention | 1 | 2015 | 9 | 0.030 |
Why?
|
Neoplasms, Second Primary | 1 | 2015 | 16 | 0.030 |
Why?
|
Platelet Count | 1 | 2015 | 21 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2015 | 23 | 0.030 |
Why?
|
Hydrocortisone | 1 | 2015 | 61 | 0.030 |
Why?
|
Stomach | 1 | 2015 | 16 | 0.030 |
Why?
|
Shock, Septic | 1 | 2015 | 28 | 0.030 |
Why?
|
Lung Diseases | 1 | 2015 | 45 | 0.030 |
Why?
|
Signal Transduction | 1 | 2019 | 666 | 0.030 |
Why?
|
Blood Loss, Surgical | 1 | 2015 | 45 | 0.030 |
Why?
|
Cause of Death | 1 | 2015 | 220 | 0.030 |
Why?
|
Spleen | 1 | 2015 | 82 | 0.030 |
Why?
|
Colon | 1 | 2015 | 56 | 0.030 |
Why?
|
Pancreas | 1 | 2015 | 79 | 0.030 |
Why?
|
Ultrasonography | 1 | 2017 | 345 | 0.030 |
Why?
|
beta Carotene | 1 | 2014 | 5 | 0.030 |
Why?
|
Folic Acid Deficiency | 1 | 2014 | 2 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2015 | 454 | 0.030 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2014 | 9 | 0.030 |
Why?
|
Folic Acid | 1 | 2014 | 12 | 0.030 |
Why?
|
Malnutrition | 1 | 2014 | 17 | 0.030 |
Why?
|
Micronutrients | 1 | 2014 | 15 | 0.030 |
Why?
|
Pneumonia | 1 | 2014 | 61 | 0.030 |
Why?
|
Serum Albumin | 1 | 2014 | 53 | 0.030 |
Why?
|
Omentum | 1 | 2014 | 26 | 0.030 |
Why?
|
Perfusion | 1 | 2014 | 64 | 0.030 |
Why?
|
Thrombosis | 1 | 2014 | 60 | 0.030 |
Why?
|
Prevalence | 1 | 2017 | 896 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2014 | 89 | 0.030 |
Why?
|
Zinc | 1 | 2014 | 32 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2014 | 79 | 0.030 |
Why?
|
Respiratory Insufficiency | 1 | 2014 | 61 | 0.030 |
Why?
|
Ovariectomy | 1 | 2014 | 147 | 0.030 |
Why?
|
Energy Intake | 1 | 2014 | 120 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2013 | 25 | 0.030 |
Why?
|
American Recovery and Reinvestment Act | 1 | 2013 | 1 | 0.030 |
Why?
|
Societies, Scientific | 1 | 2013 | 12 | 0.030 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2013 | 4 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2013 | 14 | 0.030 |
Why?
|
Research Support as Topic | 1 | 2013 | 25 | 0.030 |
Why?
|
Doxorubicin | 1 | 2013 | 55 | 0.030 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 93 | 0.030 |
Why?
|
Surgery, Plastic | 1 | 2012 | 26 | 0.030 |
Why?
|
Liver | 1 | 2015 | 464 | 0.030 |
Why?
|
Europe | 1 | 2012 | 77 | 0.030 |
Why?
|
Physician's Role | 1 | 2012 | 38 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2012 | 92 | 0.030 |
Why?
|
Physical Therapy Modalities | 1 | 2011 | 60 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2011 | 48 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2011 | 71 | 0.020 |
Why?
|
Platinum Compounds | 1 | 2010 | 3 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 680 | 0.020 |
Why?
|
Contrast Media | 1 | 2010 | 123 | 0.020 |
Why?
|
Patient Compliance | 1 | 2011 | 208 | 0.020 |
Why?
|
Temperature | 1 | 2010 | 55 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2011 | 251 | 0.020 |
Why?
|
Sex Factors | 1 | 2011 | 631 | 0.020 |
Why?
|
Colonic Polyps | 1 | 2008 | 16 | 0.020 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 2008 | 5 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2008 | 85 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2008 | 76 | 0.020 |
Why?
|
DNA Primers | 1 | 2008 | 87 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2008 | 72 | 0.020 |
Why?
|
Patient Care | 1 | 2008 | 33 | 0.020 |
Why?
|
Probability | 1 | 2008 | 150 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2008 | 140 | 0.020 |
Why?
|
Administration, Oral | 1 | 2008 | 169 | 0.020 |
Why?
|
Gender Identity | 1 | 2007 | 18 | 0.020 |
Why?
|
SEER Program | 1 | 2007 | 32 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2007 | 28 | 0.020 |
Why?
|
Alleles | 1 | 2008 | 251 | 0.020 |
Why?
|
Base Sequence | 1 | 2008 | 240 | 0.020 |
Why?
|
Leucovorin | 1 | 2007 | 20 | 0.020 |
Why?
|
Drainage | 1 | 2007 | 49 | 0.020 |
Why?
|
Sex Distribution | 1 | 2007 | 186 | 0.020 |
Why?
|
Age Distribution | 1 | 2007 | 198 | 0.020 |
Why?
|
Observer Variation | 1 | 2006 | 96 | 0.020 |
Why?
|
Vacuum | 1 | 2006 | 25 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2005 | 32 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2005 | 38 | 0.020 |
Why?
|
Fatigue | 1 | 2005 | 68 | 0.020 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2005 | 68 | 0.020 |
Why?
|
Wound Healing | 1 | 2006 | 182 | 0.020 |
Why?
|
S100 Proteins | 1 | 2004 | 18 | 0.020 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2003 | 9 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2004 | 44 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2003 | 56 | 0.010 |
Why?
|
Genes, Tumor Suppressor | 1 | 2003 | 36 | 0.010 |
Why?
|
Stereotaxic Techniques | 1 | 2003 | 23 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2003 | 57 | 0.010 |
Why?
|
Patient Care Planning | 1 | 2004 | 53 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2003 | 72 | 0.010 |
Why?
|
Down-Regulation | 1 | 2003 | 143 | 0.010 |
Why?
|
Tamoxifen | 1 | 2002 | 48 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2003 | 514 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2003 | 481 | 0.010 |
Why?
|